What Asabys Partners does

Asabys Partners is a Barcelona-based venture capital firm founded in 2018 and legally constituted as Sabadell Asabys Health Innovation Investments, S.A. The firm invests exclusively in healthcare and life-sciences innovation, targeting early-stage to clinical-stage companies across biotech, medical devices, digital health, diagnostics and healthcare services in Europe (with a Barcelona/Spain concentration) and selectively in the US, Israel, Belgium and Australia. Its portfolio of more than twenty companies is anchored by Spanish academic spin-offs from IRB Barcelona, ICREA, VHIO and the Centre for Genomic Regulation, and spans therapeutic platforms (e.g., Ona Therapeutics' ADCs, Oriva Therapeutics' women's-health pipeline, Peptomyc's MYC inhibitor OMO-103, Nuage, Augustine, Accure), medical devices (SafeHeal Colovac, Inbrain Neuroelectronics, Anaconda, Medasense), diagnostics (DeepUll, Binx Health, Quibim), digital therapeutics (XRHealth, Sidekick, Mediktor) and care services (Qida).

The firm's go-to-market is direct institutional investing: sourcing deals through its proprietary network and Spanish research institutes, conducting technical and commercial due diligence, and deploying capital alongside co-investors while acting as a hands-on partner to portfolio companies. Capital is raised and deployed through multiple vehicles, most prominently the Sabadell Asabys II fund and the Asabys Innvierte Tech Transfer fund (a €63.5M vehicle backed by CDTI's Innvierte program). LPs include Banco Sabadell, Alantra, the European Investment Bank and EU EFSI, ICO, Institut Català de Finances, Generalitat Valenciana and Institut Valencià de Finances. Revenue mechanics follow the standard European venture model: management fees on committed or invested AUM across funds, plus carried interest realized through IPOs, M&A exits and secondary sales (e.g., the Agomab acquisition of Origo Biopharma in 2021 and the merger of Amelia Virtual Care into XRHealth in 2023). Asabys aligns investment processes with UN Sustainable Development Goals and integrates ESG considerations, and is operated by a 15-person team led by co-founders Josep Ll. Sanfeliu and Clara Campàs.

Name

Asabys Partners

Legal name

Sabadell Asabys Health Innovation Investments, S.A.

Website

https://asabys.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Asabys Partners is a Barcelona-based venture capital firm founded in 2018 that invests exclusively in early- to clinical-stage healthcare and life-sciences companies across Europe, primarily through its Sabadell Asabys II fund and the CDTI-backed Asabys Innvierte Tech Transfer vehicle, backing more than 20 biotech, medtech, diagnostics and digital health portfolio companies.

Ownership category

akta.pro rank

Product category

Venture Capital / Healthcare Investment

NAICS

Portfolio Management and Investment Advice (52394), All Other Financial Investment Activities (52399)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Venture capital investing
• Healthcare venture capital
• Biotech investment
• Life sciences funding
• Medtech investment

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Investment Returns and Management Fees: As a venture capital firm, Asabys generates returns through equity appreciation in portfolio companies, carried interest on successful exits, and management fees from funds under management. Revenue is realized through IPOs, acquisitions, or secondary sales of portfolio company equity.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Asabys Partners is a Barcelona-based venture capital firm that invests in early-stage and growth-stage healthcare and life-sciences companies across biotech, healthtech, and medtech. It manages investment vehicles including the Sabadell Asabys II fund and the Asabys Innvierte Tech Transfer vehicle, deploying capital alongside hands-on operational partnership to portfolio companies in Europe and beyond.

Product overview

Asabys Partners is a Barcelona-based venture capital firm (Sabadell Asabys II fund) investing in healthcare and life-sciences innovation across Europe. The firm does not operate a single unified product; instead it manages a portfolio of 22+ portfolio companies spanning biotech, healthtech, and medtech sectors. The portfolio is organized around disruptive therapeutic and diagnostic platforms including: Ona Therapeutics (first-in-class ADCs for breast cancer), Oriva Therapeutics (women's health: endometriosis and uterine fibroids), Orikine Bio (Foldikine cytokine engineering platform), Peptomyc (MYC mini-protein inhibitors), Nuage Therapeutics (intrinsically disordered protein inhibitors), ALLOX (allosteric drug discovery platform), Accure Therapeutics (CNS disease modifiers), Augustine Therapeutics (HDAC6 inhibitors), Agomab Therapeutics (growth factor/fibrosis programs), Splice Bio (intein-based gene therapy), Inbrain Neuroelectronics (graphene brain-machine interfaces), XRHealth/Ame (extended reality therapeutic platform combining VR/AR, licensed clinicians, and data analytics), Mediktor (AI-powered medical triage assistant), Quibim (AI-driven imaging biomarker platform with regulatory-cleared devices integrated into Philips MR scanners), Medasense (AI-based objective pain monitoring), Binx Health (FDA-cleared point-of-care molecular diagnostics), DeepUll (culture-free sepsis diagnostics), SafeHeal Colovac (endoluminal bypass device for colorectal surgery), Anaconda (thrombectomy systems for ischemic stroke), Gradient Denervation (ultrasound catheter for pulmonary hypertension), Inbiomotion (MAF biomarker for bone metastasis stratification), Sidekick (gamified digital therapeutics), and Qida (B Corp home care services). The investment strategy emphasizes first-in-class and best-in-class technologies with high unmet medical need, hands-on operational partnership, and alignment with ESG and UN Sustainable Development Goals.

Differentiator

Problem solved

Functional benefit

Brands

• Sabadell Asabys II: Venture capital fund managed by Asabys Partners focused on healthcare and life sciences investments
• Asabys Innvierte Tech Transfer

Products and services

• Sabadell Asabys II Fund

Named customers5 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Partnerships

Two partnerships are on record, tiered supporting.

• OncostellaesupportingStrategic or Co-development Partner · 22 January 2026Spin-off partner contributing two advanced assets (ORV-362 and ORV-499) to Oriva Therapeutics for women's health therapies.
• MedibiofarmasupportingStrategic or Co-development Partner · 22 January 2026Spin-off partner contributing assets to Oriva Therapeutics for women's health drug development.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ysios Capital: Spanish-based venture capital firm specializing in life sciences and biotech, with comparable Spain/European focus and participation in many of the same syndicates as Asabys (e.g., Ona Therapeutics).
• Sofinnova Partners: One of Europe's largest healthcare and life-sciences VCs, investing across biotech, medtech and digital health from early to late stage. Directly comparable as a sector specialist serving European healthcare innovation.
• Forbion: European healthcare-focused VC managing multi-billion-euro funds, investing in biotech and medtech from Series A to late stage. Directly comparable as a healthcare sector specialist operating across Europe.
• Columbus Venture Partners: Spain-based venture capital firm focused on life sciences and biotechnology, frequently co-investing alongside Asabys (e.g., leading Ona Therapeutics' Series B). A close direct peer in the Spanish healthcare VC ecosystem.
• Mérieux Equity Partners: European healthcare-dedicated investment firm backing biotech, diagnostics and medtech. Co-led rounds alongside Asabys and shares a similar European, healthcare-only mandate.
• Panakès Partners: Italian-based venture capital investor in medical technologies, digital health and biotech. Co-invested with Asabys in deepull's Series C and shares a similar early-to-growth stage healthcare focus in Southern Europe.
• Inkef Capital: Dutch VC firm with a dedicated healthcare and life sciences strategy, investing in early-to-growth stage European biotech and healthtech companies. Comparable as a sector-focused European healthcare VC.

Broad incumbents

• EQT Life Sciences (formerly LSP): Large pan-European life sciences investor within the broader EQT platform, investing across all stages of healthcare. Comparable in mandate but materially larger in AUM and stage range.
• Bpifrance: French public investment bank with large healthcare and life sciences investment activities across all stages. Overlapping as an LP/co-investor in several Asabys portfolio companies (e.g., Ona Therapeutics).

Others

• CDTI (Centro para el Desarrollo Tecnológico e Industrial): Spanish public innovation funding body that commits capital to tech-transfer funds (e.g., €63.5M to Asabys Innvierte Tech Transfer) and co-invests in portfolio companies. Closely related as an LP/co-investor rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/asabyspartners
• LinkedInlinkedin.com/company/asabys-partners
• Instagraminstagram.com/asabyspartners

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments43 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asabys Partners